ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Summary
The NIH registered a new clinical trial (NCT07542717) evaluating MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy. The single-arm multicenter Phase 1 study is registered on ClinicalTrials.gov as the ASCERV study. This registry entry provides public access to trial design and eligibility information; it does not itself create compliance obligations.
What changed
The NIH registered a new clinical trial (NCT07542717) on ClinicalTrials.gov as the ASCERV study, evaluating MRG003 (anti-EGFR antibody-drug conjugate) in combination with QL1706 (PD-1/CTLA-4 bispecific antibody) in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.
For clinical trial sponsors developing similar cervical cancer or EGFR-targeted therapies, this registry entry provides reference study design and eligibility criteria. The entry is informational and does not impose compliance requirements beyond standard clinical trial registration obligations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Phase 1 NCT07542717 Kind: PHASE1 Apr 21, 2026
Abstract
This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.
Conditions: Recurrent or Metastatic Cervical Cancer
Interventions: Treatment
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.